Literature DB >> 22312159

The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors.

E Sieswerda1, A Postma, E C van Dalen, H J H van der Pal, W J E Tissing, L A J Rammeloo, W E M Kok, F E van Leeuwen, H N Caron, L C M Kremer.   

Abstract

BACKGROUND: The Late Effects of Childhood Cancer task force of the Dutch Childhood Oncology Group (DCOG LATER) developed a guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors (CCS). In this paper, we present the methods, available evidence and final recommendations of our guideline.
MATERIALS AND METHODS: A multidisciplinary working group specified clinical questions that should be answered to get to recommendations for the guideline. We carried out short or extensive evidence summaries and determined methodological quality of studies and levels of evidence in order to answer all clinical questions. When evidence was lacking for CCS, we carefully extrapolated evidence from other populations. Final recommendations were based on evidence and consensus.
RESULTS: There was high-level evidence for the increased risk of cardiac dysfunction in CCS and its main risk factors. Evidence was lacking regarding the prognosis, diagnosis and treatment of cardiac dysfunction in CCS. We recommended echocardiographic screening for asymptomatic cardiac dysfunction in CCS treated with cardiotoxic treatments and counseling about potential advantages and disadvantages of our screening recommendations.
CONCLUSION: The DCOG LATER guideline recommends risk-based screening for asymptomatic cardiac dysfunction in CCS, but it should be noted that recommendations are not completely supported by evidence in CCS.

Entities:  

Mesh:

Year:  2012        PMID: 22312159     DOI: 10.1093/annonc/mdr595

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  23 in total

Review 1.  Screening and management of adverse endocrine outcomes in adult survivors of childhood and adolescent cancer.

Authors:  Emily S Tonorezos; Melissa M Hudson; Angela B Edgar; Leontien C Kremer; Charles A Sklar; W Hamish B Wallace; Kevin C Oeffinger
Journal:  Lancet Diabetes Endocrinol       Date:  2015-04-12       Impact factor: 32.069

Review 2.  Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Authors:  Saro H Armenian; Melissa M Hudson; Renee L Mulder; Ming Hui Chen; Louis S Constine; Mary Dwyer; Paul C Nathan; Wim J E Tissing; Sadhna Shankar; Elske Sieswerda; Rod Skinner; Julia Steinberger; Elvira C van Dalen; Helena van der Pal; W Hamish Wallace; Gill Levitt; Leontien C M Kremer
Journal:  Lancet Oncol       Date:  2015-03       Impact factor: 41.316

Review 3.  Cardiomyopathy in Childhood Cancer Survivors: Lessons from the Past and Challenges for the Future.

Authors:  Matthew J Ehrhardt; Joy M Fulbright; Saro H Armenian
Journal:  Curr Oncol Rep       Date:  2016-04       Impact factor: 5.075

4.  Coronary artery disease detected by coronary computed tomography angiography in adult survivors of childhood Hodgkin lymphoma.

Authors:  Daniel A Mulrooney; Sara E Nunnery; Gregory T Armstrong; Kirsten K Ness; Deokumar Srivastava; F Daniel Donovan; Beth A Kurt; Monika L Metzger; Matthew J Krasin; Vijaya Joshi; Jean-Bernard Durand; Leslie L Robison; Melissa M Hudson; Scott D Flamm
Journal:  Cancer       Date:  2014-07-16       Impact factor: 6.860

Review 5.  Cardiovascular Risk in Survivors of Cancer.

Authors:  Henry Chen Zheng; Laura Onderko; Sanjeev A Francis
Journal:  Curr Cardiol Rep       Date:  2017-07       Impact factor: 2.931

Review 6.  Cardio-toxicity in childhood cancer survivors "Cure is not enough".

Authors:  Ulrich Neudorf; Anne Schönecker; Dirk Reinhardt
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

7.  Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.

Authors:  Elizabeth A M Feijen; Wendy M Leisenring; Kayla L Stratton; Kirsten K Ness; Helena J H van der Pal; Huib N Caron; Gregory T Armstrong; Daniel M Green; Melissa M Hudson; Kevin C Oeffinger; Leslie L Robison; Marilyn Stovall; Leontien C M Kremer; Eric J Chow
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

8.  Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331.

Authors:  Hannah-Rose Mitchell; Xiaomin Lu; Regina M Myers; Lillian Sung; Lyn M Balsamo; William L Carroll; Elizabeth Raetz; Mignon L Loh; Leonard A Mattano; Naomi J Winick; Meenakshi Devidas; Stephen P Hunger; Kelly Maloney; Nina S Kadan-Lottick
Journal:  Int J Cancer       Date:  2015-09-03       Impact factor: 7.396

9.  Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.

Authors:  Saro H Armenian; Sarah K Gelehrter; Tabitha Vase; Rajkumar Venkatramani; Wendy Landier; Karla D Wilson; Claudia Herrera; Leah Reichman; John-David Menteer; Leo Mascarenhas; David R Freyer; Kalyanasundaram Venkataraman; Smita Bhatia
Journal:  Clin Cancer Res       Date:  2014-06-19       Impact factor: 12.531

10.  Individual prediction of heart failure among childhood cancer survivors.

Authors:  Eric J Chow; Yan Chen; Leontien C Kremer; Norman E Breslow; Melissa M Hudson; Gregory T Armstrong; William L Border; Elizabeth A M Feijen; Daniel M Green; Lillian R Meacham; Kathleen A Meeske; Daniel A Mulrooney; Kirsten K Ness; Kevin C Oeffinger; Charles A Sklar; Marilyn Stovall; Helena J van der Pal; Rita E Weathers; Leslie L Robison; Yutaka Yasui
Journal:  J Clin Oncol       Date:  2014-10-06       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.